AlloVir (ALVR) Competitors $6.64 -0.45 (-6.35%) As of 10/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock ALVR vs. CGEN, HURA, ZYBT, LFVN, SKYE, TIL, EXOZ, BMEA, IKT, and KLRSShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Compugen (CGEN), TuHURA Biosciences (HURA), Zhengye Biotechnology (ZYBT), Lifevantage (LFVN), Skye Bioscience (SKYE), Instil Bio (TIL), eXoZymes (EXOZ), Biomea Fusion (BMEA), Inhibikase Therapeutics (IKT), and Kalaris Therapeutics (KLRS). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Its Competitors Compugen TuHURA Biosciences Zhengye Biotechnology Lifevantage Skye Bioscience Instil Bio eXoZymes Biomea Fusion Inhibikase Therapeutics Kalaris Therapeutics AlloVir (NASDAQ:ALVR) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings. Do insiders & institutionals have more ownership in ALVR or CGEN? 66.1% of AlloVir shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 32.1% of AlloVir shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor ALVR or CGEN? In the previous week, AlloVir and AlloVir both had 1 articles in the media. Compugen's average media sentiment score of 1.67 beat AlloVir's score of 0.00 indicating that Compugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AlloVir 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts recommend ALVR or CGEN? Compugen has a consensus target price of $4.00, suggesting a potential upside of 145.40%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Compugen 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher earnings and valuation, ALVR or CGEN? Compugen has higher revenue and earnings than AlloVir. Compugen is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlloVirN/AN/A-$190.42M-$20.23-0.33Compugen$27.86M5.22-$14.23M-$0.22-7.41 Which has more risk and volatility, ALVR or CGEN? AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Compugen has a beta of 2.61, meaning that its share price is 161% more volatile than the S&P 500. Is ALVR or CGEN more profitable? AlloVir has a net margin of 0.00% compared to Compugen's net margin of -87.45%. Compugen's return on equity of -34.77% beat AlloVir's return on equity.Company Net Margins Return on Equity Return on Assets AlloVirN/A -71.03% -61.27% Compugen -87.45%-34.77%-16.82% SummaryCompugen beats AlloVir on 10 of the 14 factors compared between the two stocks. Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.49M$307.40M$6.11B$10.54BDividend YieldN/AN/A5.66%4.70%P/E Ratio-0.33N/A86.9326.71Price / SalesN/A390.52529.88204.42Price / CashN/A22.4426.3031.09Price / Book0.2311.3912.746.57Net Income-$190.42M-$115.81M$3.30B$276.78M7 Day Performance18.36%6.37%3.55%1.98%1 Month Performance43.72%14.97%6.79%9.13%1 Year Performance-63.25%-2.97%73.23%31.60% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVirN/A$6.64-6.3%N/A-63.2%$33.49MN/A-0.33110High Trading VolumeCGENCompugen1.5774 of 5 stars$1.44-0.3%$4.00+178.7%-10.9%$128.06M$27.86M-6.5270Positive NewsGap DownHURATuHURA Biosciences1.7825 of 5 stars$2.47+0.0%$12.67+412.6%N/A$123.87MN/A0.00N/ANews CoveragePositive NewsZYBTZhengye BiotechnologyN/A$2.63+19.9%N/AN/A$123.81M$186.36M0.00278High Trading VolumeLFVNLifevantage4.2506 of 5 stars$9.74-0.2%$30.50+213.1%-16.8%$123.60M$228.53M13.16260Analyst DowngradeSKYESkye Bioscience2.4307 of 5 stars$3.93+1.2%$14.75+275.8%+33.8%$121.78MN/A-3.7111Positive NewsGap UpTILInstil Bio2.71 of 5 stars$17.58-4.8%$88.50+403.6%-62.7%$119.24MN/A-1.37410EXOZeXoZymes0.941 of 5 stars$14.21-2.0%N/AN/A$119.22M$70K0.0029Positive NewsGap UpBMEABiomea Fusion3.3932 of 5 stars$1.99-3.6%$9.50+378.6%-79.5%$118.72MN/A-0.6650Analyst ForecastIKTInhibikase Therapeutics1.3523 of 5 stars$1.59+3.6%$6.50+310.1%+31.7%$118.48MN/A-0.606KLRSKalaris Therapeutics1.3931 of 5 stars$6.20-2.4%$3.00-51.6%N/A$115.94MN/A0.00110News CoveragePositive NewsAnalyst UpgradeShort Interest ↑ Related Companies and Tools Related Companies CGEN Alternatives HURA Alternatives ZYBT Alternatives LFVN Alternatives SKYE Alternatives TIL Alternatives EXOZ Alternatives BMEA Alternatives IKT Alternatives KLRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVR) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThis soon could be the most precious company in AmericaCurrently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the ...True Market Insiders | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
